Needham Downgrades Apellis Pharmaceuticals (APLS) to Hold
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Needham analyst Joseph Stringer downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Buy to Hold.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DOJ Unveils $6.5B Healthcare Fraud Crackdown - WSJ
- Cytokinetics (CYTK) PT Raised to $118 at Mizuho
- Corbus Pharmaceuticals (CRBP) PT Lowered to $34 at Mizuho
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
